Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

IXICO plc

Healthcare US PHYOF

0.07USD
0.00(0%)

Last update at 2026-06-03T13:30:00Z

Day Range

0.070.07
LowHigh

52 Week Range

0.0030.77
LowHigh

Fundamentals

  • Previous Close 0.07
  • Market Cap8.31M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.09200M
  • Revenue TTM6.67M
  • Revenue Per Share TTM0.14
  • Gross Profit TTM 5.24M
  • Diluted EPS TTM-0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax -1.36100M 0.89M 1.16M 0.86M 0.37M
Minority interest - - - - 0.00000M
Net income -1.17800M 1.03M 1.57M 0.95M 0.43M
Selling general administrative 4.17M 3.48M 3.58M 4.40M 3.90M
Selling and marketing expenses - - - - -
Gross profit 3.27M 5.24M 6.02M 6.35M 4.94M
Reconciled depreciation 0.62M 0.64M 0.61M 0.44M 0.11M
Ebit - 0.91M 1.12M 0.86M 0.36M
Ebitda - 1.56M 1.79M 1.31M 0.50M
Depreciation and amortization - - - - -
Non operating income net other - - - - 0.00000M
Operating income -1.43700M 0.76M 1.16M 0.84M 0.39M
Other operating expenses - 0.69M 0.45M 0.61M 0.59M
Interest expense 0.03M 0.03M 0.02M 0.02M 0.00000M
Tax provision -0.18300M -0.14700M -0.41500M -0.09400M -0.06600M
Interest income 0.10M 0.01000M 0.00100M 0.02M 0.00200M
Net interest income 0.08M -0.02300M -0.02100M 0.00200M 0.00200M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense - -0.14700M -0.41500M -0.09400M -0.06600M
Total revenue 6.67M 8.64M 9.19M 9.53M 7.56M
Total operating expenses 8.10M 7.88M 8.03M 8.69M 7.17M
Cost of revenue 3.40M 3.40M 3.17M 3.19M 2.62M
Total other income expense net - - - - 0.00200M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -1.17800M 1.03M 1.57M 0.95M 0.43M
Net income applicable to common shares - 1.03M 1.51M 0.95M 0.43M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 12.99M 14.65M 14.15M 12.10M 10.70M
Intangible assets 6.15M 4.59M 2.71M 0.80M 0.29M
Earning assets - - - - -
Other current assets - 0.10M 0.11M - 0.00000M
Total liab 1.56M 2.16M 2.93M 2.98M 2.78M
Total stockholder equity 11.43M 12.49M 11.22M 9.12M 7.92M
Deferred long term liab - - - - 0.00000M
Other current liab - 0.85M 0.53M 1.04M 0.62M
Common stock - 0.48M 0.48M 0.47M 0.47M
Capital stock 0.48M 0.48M 0.48M 0.47M 7.92M
Retained earnings -7.36000M -6.23400M -7.34500M -9.38200M -10.53300M
Other liab - 0.03M 0.11M 0.26M 0.00000M
Good will - - - - 0.00000M
Other assets - - - - 0.00000M
Cash 4.03M 5.77M 6.68M 7.95M 7.26M
Cash and equivalents - - - - -
Total current liabilities 1.28M 1.74M 2.15M 2.67M 2.78M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - - 0.00000M
Short long term debt - - - - 0.00000M
Short long term debt total - - - - -
Other stockholder equity - -66.55700M -66.46000M -66.46900M -66.45300M
Property plant equipment - 0.82M 1.08M 1.01M 0.32M
Total current assets 6.29M 9.25M 10.47M 10.29M 10.09M
Long term investments - - - - 0.00000M
Net tangible assets - 7.91M 8.77M 8.32M 7.63M
Short term investments - - - - 0.00000M
Net receivables 0.94M 2.73M 3.12M 1.79M 2.41M
Long term debt - - - - 0.00000M
Inventory - - - - 0.00000M
Accounts payable 0.09M 0.25M 0.73M 0.18M 0.60M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income - - - - 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other - - - - 0.00000M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 6.70M 5.40M 3.79M 1.81M 0.61M
Capital lease obligations 0.39M 0.52M 0.60M 0.21M 0.00000M
Long term debt total - - - - 0.00000M
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments -1.86400M -2.23900M -2.15300M -1.12200M -0.51300M
Change to liabilities - -0.69600M -0.36600M -0.14600M -0.32500M
Total cashflows from investing activities - -2.23900M -2.15300M -1.12200M -0.51300M
Net borrowings - -0.11400M -0.04400M -0.17700M -0.17700M
Total cash from financing activities - -0.11400M 0.27M -0.11200M 0.05M
Change to operating activities - - - - 0.00000M
Net income -1.17800M 1.03M 1.51M 0.95M 0.43M
Change in cash -1.71800M -0.91500M -1.26100M 0.68M -0.59700M
Begin period cash flow 5.77M 6.68M 7.95M 7.26M 7.86M
End period cash flow 4.03M 5.77M 6.68M 7.95M 7.26M
Total cash from operating activities 0.30M 1.42M 0.61M 1.92M -0.13000M
Issuance of capital stock 0.00200M 0.00000M 0.31M 0.07M 0.05M
Depreciation 0.62M 0.49M 0.50M 0.39M 0.10M
Other cashflows from investing activities - 0.00600M 0.00100M 0.02M 0.00400M
Dividends paid - - - - 0.00000M
Change to inventory - - - - 0.00000M
Change to account receivables - 0.28M -1.09300M 0.30M -0.23900M
Sale purchase of stock - - - - 0.00000M
Other cashflows from financing activities - - - -0.01800M -0.01800M
Change to netincome - 0.17M -0.04900M 0.38M -0.11000M
Capital expenditures 1.96M 0.19M 0.17M 0.69M 0.22M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital 0.96M -0.41600M -1.52200M 0.17M -0.56400M
Stock based compensation 0.05M 0.08M 0.20M 0.18M 0.11M
Other non cash items -0.43100M -0.29300M -0.19200M -0.16400M -0.15700M
Free cash flow -1.66100M -0.82100M -1.54100M 0.79M -0.64700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PHYOF
IXICO plc		 - -% 0.07 - - 1.24 0.50 0.55 -5.1922
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, the Netherlands, Ireland, rest of Europe, and the United States. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, an online digital platform for clinics; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. In addition, the company focuses in therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, and orphan and rare diseases. Further, the company engages in the data collection and analysis of neurological disorders. Additionally, it offers drug development analytics, imaging operation, post marketing surveillance, and consultancy services; and end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.

IXICO plc

Griffin Court, London, United Kingdom, EC1A 9PN

Key Executives

Name Title Year Born
Mr. Giulio Cerroni CEO & Director 1962
Mr. Grant Nash CFO, Company Sec. & Exec. Director NA
Prof. Daniel Rueckert Co-Founder & Member of Scientific Advisory Board NA
Prof. Derek Lionel Glendon Hill Co-Founder and Pres of Regulatory Science & External Relations 1966
Prof. David Hawkes Co-Founder & Member of Scientific Advisory Board NA
Prof. Joseph Hajnal Co-Founder & Member of Scientific Advisory Board NA
Mr. Marcus Thornton Chief Operating Officer NA
Mr. Mark Austin Director of Technology NA
Dr. Robin Wolz Chief Scientific Officer NA
Ms. Hannah Esfahanian HR Mang. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.